

Denka to begin AMED COVID-19 Subsidy Project
Conclusion of Agreement to Supply Equipment and Reagents for the Project with Taiwan-Based
PlexBio

Denka Company Limited (headquarters: Chuo-ku, Tokyo; president: Manabu Yamamoto; hereinafter “Denka”) announces that it has begun a project to develop multiplex molecular diagnostic systems for diagnosing multiple diseases, including COVID-19, under an AMED subsidy program that was announced on June 10. Accompanying this project, on August 12, Denka concluded an agreement to supply equipment and reagents for the project with PlexBio Co., Ltd. (headquarters: Taipei, Taiwan; CEO: Dr. Dean Tsao; hereinafter “PB”). Denka has a business alliance with PB and owns a 33.4% equity stake. Denka has also received notification of the grant from AMED.

The purpose of this project is to evaluate and demonstrate the performance of a genetic diagnostic testing system (instrument and reagents) which can simultaneously measure the existence of multiple respiratory infections, including the COVID-19, and to develop a novel platform that produces results more efficiently, conveniently, with reduced labor. PB’s π code technology enables the highly sensitive detection of microorganisms as well as a simultaneous analysis of multiple items. The features of the π code technology are most suitable for the project, which is why the technology was selected. This project will have minimal financial impact to Denka’s consolidated performance this fiscal year.

As a part of its responsibility to society regarding measures to address COVID-19, Denka is advancing research and development from various aspects, including antigen testing kits, to help improve testing systems to meet the needs of medical care facilities.

References:

- Denka Files Application for Japanese in Vitro Diagnostics Approval of a Simple and Rapid Testing Kit Infection for the COVID-19 Novel Coronavirus, July 20, 2020
https://www.denka.co.jp/eng/storage/news/pdf/290/20200720_denka_covid19_testingkit_en.pdf
- Denka to Step up Business Alliance with Taiwan-Based PlexBio through the Acquisition of Shares Offered via Third-Party Allotment, July 30, 2019
https://www.denka.co.jp/eng/storage/news/pdf/240/20190730_pb_e.pdf

About Denka:

Denka is a chemical manufacturer headquartered in Chuo-ku, Tokyo. The company specializes in developing business activities on a global scale across a wide range of fields, from inorganic and organic chemicals, to electronic materials and pharmaceuticals. Founded in 1915, Denka has steadily continued to develop and manufacture products that contribute to the development of society by fully utilizing its unique concepts and technological capabilities. Upholding its corporate slogan, “Possibility of chemistry,” the company and its president, Manabu Yamamoto, are committed to contributing to the sound development of society while sincerely tackling the challenges that society is now confronting.

[For Inquiries about This Press Release from Media]

Corporate Communications Dept. Tel : +81-3-5290-5511